Comparative evaluation of the efficacy of an incomplete cytoreduction application in combination with systemic therapy and systemic therapy as mono-therapy in patients with metastatic clear-cell renal cell carcinomas

  • Authors: Borisov PS1, Orlova RV1,2,3, Shkolnik MI4, Karlov PA1
  • Affiliations:
    1. Saint Petersburg City Oncology Clinic
    2. Saint Petersburg State University
    3. L.G.Sokolov Clinical Hospital №122
    4. Russian Scientific Center of Radiology and Surgical Technologies
  • Issue: Vol 17, No 4 (2015)
  • Pages: 26-33
  • Section: Articles
  • URL: https://modernonco.orscience.ru/1815-1434/article/view/27018
  • Cite item

Abstract


The introduction of targeted therapy drugs into the practice of oncology urologists has improved the results of treatment of patients with metastatic clear-cell renal cell carcinomas (mCCRCC). Correctly chosen elements of systemic therapy will help specialist to control the course of the metastatic process for more than 2 years. But, sooner or later, the refractoriness will be developed at each stage of systemic treatment therefore it is important to find the existing methods accompanied the systemic therapy. These methods should increase and prolong the targeted drugs action or delay the time before the first targeted drugs prescription. Complex approach in the treatment of metastatic solid tumors is actively used in cancer therapy every day. Cytoreductive nephrectomy and complete cytoreduction(ectomy for metastasis) are widely used in the world practice, demonstrating the improvement of survival rates, while the necessary of incomplete cytoreductive surgical intervention application (iCSI) is a controversial problem in oncological community. However, the success of complex approach in the treatment of metastatic tumors in other locations gives reason to try this method once again in mCCRCC therapy.The aim is to compare the efficacy of complex approach consisted of targeted therapy and iCSI application in comparison with the targeted therapy as mono-therapy in the treatment of metastatic RCC (mRCC). Conclusions: the choice of combined treatment in patients with mCCRCC is proved. Survival rates in the group using combined treatment comparable to control group show the justification of this treatment method application. The study shows the potential efficacy of complex approach application as a therapy in mCCRCC patients. iCSI can also be used as independent treatment method in specific group of patients. This can help to increase the observation period in case of mCCRCC patients of 9 months.The efficacy of targeted therapy drugs application significantly higher in comparison with the immunotherapy usage in more than 2 times (17 and 13 months versus 6 months).

Full Text

Restricted Access

About the authors

P S Borisov

Saint Petersburg City Oncology Clinic

197022, Russian Federation, Saint Petersburg, 2-ia Berezovaia alleia, d. 3/5

R V Orlova

Saint Petersburg City Oncology Clinic; Saint Petersburg State University; L.G.Sokolov Clinical Hospital №122

199034, Russian Federation, Saint Petersburg, Universitetskaia nab. d. 7/9

M I Shkolnik

Russian Scientific Center of Radiology and Surgical Technologies

197758, Russian Federation, Saint Petersburg, pos. Pesochnyi,Leningradskaia ul., d. 70

P A Karlov

Saint Petersburg City Oncology Clinic

197022, Russian Federation, Saint Petersburg, 2-ia Berezovaia alleia, d. 3/5

References

  1. Матвеев В.Б., Волкова М.И. Последовательная терапия при диссеминированном раке почки. Онкоурология. 2013; 1: 28-33.
  2. Motzer R.J, Hutson T.E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal - cell carcinoma. N Engl J Med 2007; 356 (2): 115-24.
  3. Escudier B, Pluzanska A, Koralewski P et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double - blind phase III trial. Lancet 2007; 370 (9605): 2103-11.
  4. Rini B.I, Halabi S, Rosenberg J.E et al. Bevacizumab plus interferon alfa compared with interferon alfamonotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-8.
  5. Escudier B, Szczylik C, Eisen T et al. Randomized III phase of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]. Proc Am Soc Clin Oncol 2005; 23.
  6. Sternberg C.N, Davis I.D, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6): 1061-8.
  7. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, Interferon alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007; 356 (22): 2271-81.
  8. Rini B.I, Escudier B, Tomczak P. Axitinib versus Sorafenib as second - line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol 2011; 29 (Suppl.; abstr. 4503).
  9. Motzer R.J, Escudier B.J, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double - blind, randomized, placebocontrolled phase III trial. Lancet 2008; 372 (9637): 449-56.
  10. Ljunberg B et al. Guidelines on Renal Cell Carcinoma. Eur Ass Urol 2015; p. 36-9.
  11. Di Lorenzo G, Buonerba C, Federico P et al. Third Line Sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic. Renal Cell Carc 2010; 58: 62.
  12. Gruenwald V, Seidel C, Fenner M. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Abstr. 414. Available at: http://www.asco.org/acov2/Meetings/Abstracts
  13. Alt A.L, Boorjian S.A, Lohse C.M et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117 (13): 2873-8.
  14. Kwak C, Park Y.H, Jeong C.W et al. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: Comparison with conservative treatment. Urol Int 2007; 79 (2): 145-51.
  15. Lee S.E, Kwak C, Byun S.S et al. Metastatectomy prior to immunochemotherapy for metastatic renal cell Carcinoma. Urol Int 2006; 76 (3): 256-63.
  16. Petralia G, Roscigno M, Zigeuner R et al. Complete metastasectomy is an independent predictor of cancerspecific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol Suppl 2010; 9: 162.
  17. Staehler M, Kruse J, Haseke N et al. Metastasectomy significantly prolongs survival in patients with metastatic renal cancer. Eur Urol Suppl 2009; 8: 18.
  18. Eggener S.E, Yossepowitch O, Kundu S et al. Risk score and metastasectomy independently impact prognosisof patients with recurrent renal cell carcinoma. J Urol 2008; 180: 873-8.
  19. Давыдов М.И., Матвеев В.Б., Полоцкий Б.Е. и др. Хирургическое лечение метастазов рака почки в легких. Рос. онкол. журн. 2003; 4: 15-9.
  20. Kavolius J.P, Mastorakos D.P, Pavlovich C et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-6.
  21. Fuchs B et al. Clinical Orthop Relat Res 2005; 431: 187-92.
  22. Кострицкий С.В., Широкорад В.И., Семенов Д.В. и др. Хирургическое лечение метастазов рака почки в длинные трубчатые кости. Онкоурология. 2013; 2: 18-20.

Statistics

Views

Abstract - 13

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies